@article{16dc60946a144353ae0a5a2f30ee61ba,
title = "The Imperial College Cambridge Manchester (ICCAM) platform study: An experimental medicine platform for evaluating new drugs for relapse prevention in addiction. Part A: Study description",
keywords = "Addiction, dopamine D3 receptor, functional magnetic resonance imaging, neurokinin 1 receptor, μ-opioid receptor",
author = "Paterson, {Louise M.} and Flechais, {Remy S.A.} and Anna Murphy and Reed, {Laurence J.} and Sanja Abbott and Venkataramana Boyapati and Rebecca Elliott and David Erritzoe and Ersche, {Karen D.} and Yetunde Faluyi and Luca Faravelli and Emilio Fernandez-Egea and Kalk, {Nicola J.} and Kuchibatla, {Shankar S.} and John McGonigle and Antonio Metastasio and Inge Mick and Liam Nestor and Csaba Orban and Filippo Passetti and Rabiner, {Eugenii A.} and Smith, {Dana G.} and John Suckling and Roger Tait and Taylor, {Eleanor M.} and Waldman, {Adam D.} and Robbins, {Trevor W.} and Deakin, {Jf William} and Nutt, {David J.} and Lingford-Hughes, {Anne R.}",
note = "Funding Information: ICCAM platform collaborators: David Nutt, Anne Lingford-Hughes, Louise Paterson, John McGonigle, Remy Flechais, Csaba Orban, JF William Deakin, Rebecca Elliott, Anna Murphy, Eleanor Taylor, Trevor Robbins, Karen Ersche, John Suckling, Dana Smith, Laurence Reed, Filippo Passetti, Luca Faravelli, David Erritzoe, Inge Mick, Nicola Kalk, Adam Waldman, Liam Nestor, Shankar Kuchibatla, Venkataramana Boyapati, Antonio Metastasio, Yetunde Faluyi, Emilio Fernandez-Egea, Sanja Abbott, Barbara Sahakian, Valerie Voon, Ilan Rabiner. The research was carried out at the NIHR/Wellcome Trust Imperial Clinical Research Facility, the NIHR/Wellcome Trust Cambridge Research Facility and Clinical Trials Unit at Salford Royal NHS Foundation Trust, and is supported by the North West London, Eastern and Greater Manchester NIHR Clinical Research Networks. The views expressed are those of the author(s) and not necessarily those of the Medical Research Council, the NHS, the NIHR or the Department of Health. The authors wish to thank research assistants Claire Whitelock, Heather Agyepong, Rania Christoforou and Natalie Cuzen for their help with data collection, Dr Sharon Morein-Zamir for her help with data extraction from reinforced GoNogo task, MR physicist Rex Newbould and MR technician, Jonathan Howard for their assistance with MR acquisition and task set-up. The authors also wish to thank their recruitment partners; Imperial College Healthcare NHS Trust, Central and North West London NHS Trust, Camden and Islington NHS Trust, Cambridge University Hospitals NHS Foundation Trust, Norfolk and Suffolk NHS Foundation Trust, Cambridge and Peterborough NHS Foundation Trust, South Staffordshire and Shropshire NHS Foundation Trust, Manchester Mental Health NHS and Social Care Trust, Greater Manchester West NHS Foundation Trust, Pennine Care NHS Foundation Trust, Salford Royal NHS Foundation Trust, Addaction, Foundation 66 and CRI (Crime Reduction Initiative). Funding Information: The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This article presents independent research funded by the MRC as part of their addiction initiative (grant number G1000018). GSK kindly funded the functional and structural MRI scans that took place at Imperial College and provided the GSK598809 and vofopitant medication. Funding Information: JF William Deakin currently advises or carries out research funded by Autifony, Sunovion, Lundbeck, AstraZeneca and Servier. All payment is to the University of Manchester. Funding Information: Anne Lingford-Hughes has received honoraria from Lundbeck and research support from GSK for a PhD studentship. Funding Information: Emilio Fernandez-Egea has done consultancy for Roche and received research funding from Genus Pharmaceuticals. Publisher Copyright: {\textcopyright} The Author(s) 2015.",
year = "2015",
month = sep,
day = "23",
doi = "10.1177/0269881115596155",
language = "English",
volume = "29",
pages = "943--960",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications",
number = "9",
}